CyberMedica Cures Drug Discovery Process Bottlenecks while Safely Improving Responsible Human Research Around the World.

Kennebunkport, Maine (PRWEB) December 8, 2003 -- CyberMedica gives away open standards software aimed squarely at accelerating the drug and device discovery process with improved safety for patients. Fiercely competitive pharmaceutical and medical device manufacturers have inundated the clinical trial system. Ethics review committees also known as institutional review boards or IRBs, have often resorted to the lowest common denominator, paper. Expensive proprietary solutions have failed to achieve critical mass and absent a standard, most IRBs have preferred to build idiosyncratic local applications. Successful trials are indeed slowed by this inefficiency and failed trials are often neither identified early enough to minimize harmful, sometimes deadly, adverse events to patients nor timely ended to make way for new trials and, perhaps, the next major cure.

Kennebunkport, Maine (PRWEB) December 8, 2003 --CyberMedica gives away open standards software aimed squarely at accelerating the drug and device discovery process with improved safety for patients. Fiercely competitive pharmaceutical and medical device manufacturers have inundated the clinical trial system. Ethics review committees also known as institutional review boards or IRBs, have often resorted to the lowest common denominator, paper. Expensive proprietary solutions have failed to achieve critical mass and absent a standard, most IRBs have preferred to build idiosyncratic local applications. Successful trials are indeed slowed by this inefficiency and failed trials are often neither identified early enough to minimize harmful, sometimes deadly, adverse events to patients nor timely ended to make way for new trials and, perhaps, the next major cure.

In a recent communication with CyberMedica Chairman Robert E. Stewart, Edward Greg Koski, MD, PHD Current Advisory Board Chairman for the World Health Organizations Strategic Initiative for Developing Capacity for Ethical Review (WHO- SIDCER) and until recently Director of the United States Department of Health and Human Services Office for Human Research Protections (OHRP) wrote: I believe that offering a web-based system for use in developing countries around the world may have precisely the harmonizing effect you envision, and would do wonders for improving the conditions and capabilities for doing responsible human research around the world almost overnight." This could be an amazing opportunity. I believe there could be enormous potential for your actions to do enormous good to promote better health through responsible research globally. I can easily envision your efforts being the catalyst for others, such as the major pharmaceutical and device companies to join in an effort that would capture the moral high ground in human research that could not otherwise be possible." Koski, Greg, M.D., RE: Improving IRB's," 1 NOVEMBER 2003, via email.

Robert E. Stewart CyberMedica Chairman and Chief Executive Officer states: Our mission is to save lives and create cures faster by providing market efficiencies through a common open platform. Philanthropically gifting licenses to our software and intellectual property is the fastest way to reach critical mass adoption and do the most good. CyberMedica is currently seeking financial support from the industry to coordinate, support and maintain the standard."

CyberMedica was founded in 1998 with the mission of accelerating the drug discovery process. At a cost exceeding fifteen million dollars ($15M) eIRB is an internet based management system for doctors and hospitals to use for the efficient operations of the peer-review ethics committees responsible for the oversight of human clinical trials for new drugs, devices and techniques. These ethics review committees also known as Institutional Review Boards or IRBs are the governing bodies of human medical research. CyberMedicas software automates the currently paper-intensive, manual process used today. IRBs are inundated by pharmaceutical companies, medical device manufacturers and physicians with requests to trial new drugs, new devices, and new medical techniques. The inherent inefficiencies in this critical process cause successful trials to be delayed thus retarding the introduction of new drugs, devices and techniques to the market and slowing relief for those afflicted. Additionally, unsuccessful trials are not identified as quickly, too often with devastating, sometimes deadly, consequences to participants, and finally, already limited IRB resources are constrained from making the next successful discovery. CyberMedica is a privately held not-for-profit corporation.
CyberMedicas eIRB solutions are available immediately.

About CyberMedica

CyberMedica is a not-for-profit organization created to participate as the standards provider of peer-reviewed infrastructure platforms for technology to deliver secure open-systems standards for collaborative scientific research for device manufacturers, biotech and pharmaceutical companies worldwide. CyberMedica platforms are engineered to provide a real-time encrypted data-centric and ISO-auditable decision support and data management systems. CyberMedicas systems and its facilities were architected to B1 standards of security integrity and were developed with ISO-auditable processes, SEI software systems engineering standards and total quality UML documentation.

CONTACT INFORMATION:

Contact Robert E. Stewart, Chairman
CyberMedica Foundation
21A Western Avenue
Kennebunk, Maine 04043
Phone: 207-967-0800
Fax: 207-967-0817
Email: info@cybermedica.com
Website: www.CyberMedica.com

Safe Harbor Statement

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by phrases such as CyberMedica or its management "believes," "expects," "anticipates," "foresees," "forecasts," "estimates" or other words or phrases of similar import. Similarly, such statements in this release that describe the company's business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

###